KR101759362B1 - 이자섬 이식에서 보조제로서 ｃｘｃｒ1/2의 억제제 - Google Patents

이자섬 이식에서 보조제로서 ｃｘｃｒ1/2의 억제제 Download PDF

Info

Publication number
KR101759362B1
KR101759362B1 KR1020127010732A KR20127010732A KR101759362B1 KR 101759362 B1 KR101759362 B1 KR 101759362B1 KR 1020127010732 A KR1020127010732 A KR 1020127010732A KR 20127010732 A KR20127010732 A KR 20127010732A KR 101759362 B1 KR101759362 B1 KR 101759362B1
Authority
KR
South Korea
Prior art keywords
transplantation
reparixin
islet
glucose
rats
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020127010732A
Other languages
English (en)
Korean (ko)
Other versions
KR20120083440A (ko
Inventor
로렌조 피에몬티
루이사 다폰치오
마르셀로 알레그레티
Original Assignee
돔페 파르마써티씨 에스.피.에이.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 돔페 파르마써티씨 에스.피.에이. filed Critical 돔페 파르마써티씨 에스.피.에이.
Publication of KR20120083440A publication Critical patent/KR20120083440A/ko
Application granted granted Critical
Publication of KR101759362B1 publication Critical patent/KR101759362B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/50—Compounds containing any of the groups, X being a hetero atom, Y being any atom
    • C07C311/51—Y being a hydrogen or a carbon atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
KR1020127010732A 2009-10-06 2010-10-06 이자섬 이식에서 보조제로서 ｃｘｃｒ1/2의 억제제 Expired - Fee Related KR101759362B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09172364.3 2009-10-06
EP09172364A EP2308484A1 (en) 2009-10-06 2009-10-06 Inhibitors of cxcr1/2 as adjuvants in the transplant of pancreatic islets
PCT/EP2010/064921 WO2011042466A1 (en) 2009-10-06 2010-10-06 Inhibitors of cxcr1/2 as adjuvants in the transplant of pancreatic islets

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020177015626A Division KR101817912B1 (ko) 2009-10-06 2010-10-06 이자섬 이식에서 보조제로서 ｃｘｃｒ1/2의 억제제

Publications (2)

Publication Number Publication Date
KR20120083440A KR20120083440A (ko) 2012-07-25
KR101759362B1 true KR101759362B1 (ko) 2017-07-18

Family

ID=41818891

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020127010732A Expired - Fee Related KR101759362B1 (ko) 2009-10-06 2010-10-06 이자섬 이식에서 보조제로서 ｃｘｃｒ1/2의 억제제
KR1020177015626A Expired - Fee Related KR101817912B1 (ko) 2009-10-06 2010-10-06 이자섬 이식에서 보조제로서 ｃｘｃｒ1/2의 억제제

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020177015626A Expired - Fee Related KR101817912B1 (ko) 2009-10-06 2010-10-06 이자섬 이식에서 보조제로서 ｃｘｃｒ1/2의 억제제

Country Status (24)

Country Link
US (1) US20120202884A1 (enExample)
EP (2) EP2308484A1 (enExample)
JP (2) JP5834010B2 (enExample)
KR (2) KR101759362B1 (enExample)
CN (2) CN104906572A (enExample)
AU (1) AU2010305385B2 (enExample)
BR (1) BR112012007991B8 (enExample)
CA (1) CA2775902C (enExample)
CY (1) CY1115018T1 (enExample)
DK (1) DK2485723T3 (enExample)
EA (1) EA021298B1 (enExample)
ES (1) ES2451349T3 (enExample)
HK (1) HK1213777A1 (enExample)
HR (1) HRP20140202T1 (enExample)
IL (1) IL219037A (enExample)
ME (1) ME01719B (enExample)
MX (1) MX2012004082A (enExample)
NZ (1) NZ599172A (enExample)
PL (1) PL2485723T3 (enExample)
PT (1) PT2485723E (enExample)
RS (1) RS53249B (enExample)
SI (1) SI2485723T1 (enExample)
SM (1) SMT201400033B (enExample)
WO (1) WO2011042466A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2308484A1 (en) * 2009-10-06 2011-04-13 Dompé S.p.a. Inhibitors of cxcr1/2 as adjuvants in the transplant of pancreatic islets
EP2308485A1 (en) 2009-10-06 2011-04-13 Dompé S.p.a. Sulfonamides for the prevention of diabetes
CN103159652B (zh) * 2011-12-19 2016-06-08 天津市国际生物医药联合研究院 亚磺酰胺类化合物的制备及其应用
WO2014205127A2 (en) 2013-06-18 2014-12-24 New York University Cellular factors involved in the cytotoxicity of staphylococcus aureus leukocidins: novel therapeutic targets
CN117503933A (zh) 2016-10-03 2024-02-06 儿童医疗中心公司 糖尿病肾病的预防和治疗

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009117710A2 (en) 2008-03-20 2009-09-24 Carolus Therapeutics, Inc. Methods of treating inflammation

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1303249B1 (it) 1998-10-23 2000-11-06 Dompe Spa Alcune n-(2-aril-propionil)-solfonammidi e preparazionifarmaceutiche che le contengono.
WO2001078653A2 (en) * 2000-04-14 2001-10-25 Millennium Pharmaceuticals, Inc. Graft rejection inhibition with ccr2 inhibitors
AU2001253496A1 (en) * 2000-04-14 2001-10-30 Millennium Pharmaceuticals, Inc. Treating graft rejection with cxcr3 inhibitors
ITMI20010206A1 (it) * 2001-02-02 2002-08-02 Dompe Spa Uso della metansolfonammide di (r)-ibuprofene e dei suoi sali non tossici per la preparazione di medicamenti per il trattamento e la prevenz
CN1934077B (zh) 2004-03-23 2010-09-29 冬姆佩制药股份公司 2-苯基丙酸衍生物及含有它们的药物组合物
DE602004003673T2 (de) 2004-03-25 2007-10-04 Dompe' Pha.R.Ma S.P.A. Verwendung von N-(2-Aryl-propionyl)-sulfonamiden zur Behandlung von Rückenmarkverletzungen
US20050261762A1 (en) * 2004-05-21 2005-11-24 Medtronic Vascular, Inc. Medical devices to prevent or inhibit restenosis
AU2005283326B2 (en) * 2004-09-13 2011-07-21 Ono Pharmaceutical Co., Ltd. Nitrogenous heterocyclic derivative and medicine containing the same as an active ingredient
EP2040690B1 (en) * 2006-06-28 2014-08-06 Sanofi Inhibitors of cxcr2
JP2010504996A (ja) * 2006-09-26 2010-02-18 ケース ウエスタン リザーブ ユニバーシティ サイトカインシグナリング
EP2308484A1 (en) * 2009-10-06 2011-04-13 Dompé S.p.a. Inhibitors of cxcr1/2 as adjuvants in the transplant of pancreatic islets

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009117710A2 (en) 2008-03-20 2009-09-24 Carolus Therapeutics, Inc. Methods of treating inflammation

Also Published As

Publication number Publication date
RS53249B (sr) 2014-08-29
CN102665703B (zh) 2016-04-20
AU2010305385A1 (en) 2012-04-26
AU2010305385B2 (en) 2016-04-21
BR112012007991A2 (pt) 2017-07-25
BR112012007991B8 (pt) 2021-05-25
EA021298B1 (ru) 2015-05-29
ES2451349T3 (es) 2014-03-26
HK1213777A1 (zh) 2016-07-15
CN104906572A (zh) 2015-09-16
HRP20140202T1 (en) 2014-05-23
HK1175993A1 (zh) 2013-07-19
CA2775902C (en) 2016-11-29
BR112012007991B1 (pt) 2020-12-15
EP2308484A1 (en) 2011-04-13
US20120202884A1 (en) 2012-08-09
NZ599172A (en) 2014-03-28
PL2485723T3 (pl) 2014-07-31
SMT201400033B (it) 2014-07-07
PT2485723E (pt) 2014-03-13
JP2013506704A (ja) 2013-02-28
JP5834010B2 (ja) 2015-12-16
CA2775902A1 (en) 2011-04-14
EP2485723A1 (en) 2012-08-15
ME01719B (me) 2014-09-20
IL219037A (en) 2015-01-29
CN102665703A (zh) 2012-09-12
IL219037A0 (en) 2012-06-28
CY1115018T1 (el) 2017-01-25
EA201270513A1 (ru) 2012-11-30
JP2015145404A (ja) 2015-08-13
KR20170068625A (ko) 2017-06-19
KR20120083440A (ko) 2012-07-25
MX2012004082A (es) 2012-07-25
EP2485723B1 (en) 2013-12-11
SI2485723T1 (sl) 2014-06-30
JP6097328B2 (ja) 2017-03-15
KR101817912B1 (ko) 2018-02-21
WO2011042466A1 (en) 2011-04-14
DK2485723T3 (en) 2014-03-17

Similar Documents

Publication Publication Date Title
KR101650264B1 (ko) 보체 활성을 저해함으로써 동종이식편의 생존 연장
Lakey et al. Current status of clinical islet cell transplantation
KR101759362B1 (ko) 이자섬 이식에서 보조제로서 ｃｘｃｒ1/2의 억제제
JP2019135262A (ja) 免疫調節のための４−メチルウンベリフェロン処置
HK1222342A1 (en) Prolongation of survival of an allograft by inhibiting complement activity
JP2002506446A (ja) ランゲルハンス島組織の移植のためのｃｄ１５４遮断治療
RU2257895C2 (ru) Применение (r)-ибупрофенметансульфонамида и его солей для лечения и предотвращения реакций отторжения трансплантируемых органов
AU2010305384B2 (en) Sulfonamides for the prevention of diabetes
Koike et al. Pretreatment with olprinone hydrochloride, a phosphodiesterase III inhibitor, attenuates lipopolysaccharide-induced lung injury via an anti-inflammatory effect
HK1175993B (en) Inhibitors of cxcr1/2 as adjuvants in the transplant of pancreatic islets
Elsedfy Cytokines and beta-cell destruction
HK1101962B (en) Prolongation of survival of an allograft by inhibiting complement activity

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

N231 Notification of change of applicant
PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

D13-X000 Search requested

St.27 status event code: A-1-2-D10-D13-srh-X000

D14-X000 Search report completed

St.27 status event code: A-1-2-D10-D14-srh-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

A107 Divisional application of patent
AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PX0901 Re-examination

St.27 status event code: A-2-3-E10-E12-rex-PX0901

PX0701 Decision of registration after re-examination

St.27 status event code: A-3-4-F10-F13-rex-PX0701

X701 Decision to grant (after re-examination)
GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20230713

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20230713